Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlloJoin for Knee Osteoarthritis
NCT04208646Phase 2Completed
- Sponsor
- AbelZeta
- Start
- May 2020
- Primary completion
- Jun 2021
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of allogenic adipose tissue-derived mesenchymal progenitor cells in osteoarthritis (OA) (3 arms), sponsored by AbelZeta. Primary endpoint: WOMAC Score at 24 weeks. Started May 2020; status: completed.
02
Drugs
allogenic adipose tissue-derived mesenchymal progenitor cells
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT04208646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04208646.